ConductScience.org, home

85,013 comparisons from ClinicalTrials.gov.

85,013 comparisons

Most participants first33,758 with no events in either group come last3,461 to 3,480 of 85,013

Show the results as
ComparisonWith the outcomeRisk difference, 95% intervalParticipantsTrial
Azithromycin vs Placebo: Participants With Endometritis and/or Wound Infection and/or Other Post-cesarean Infections (Occurring Within 6 Weeks of Delivery)62 of 1,018

119 of 992

-5.9 points

-8.4 to -3.4

2,010NCT01235546

Study of Effectiveness and Safety of Azithromycin-based Extended-spectrum Prophylaxis to Prevent Post Cesarean Infection

Placebo and Standard of Care vs Azithromycin and Standard of Care: Infant Pyloric Stenosis1 of 992

2 of 1,018

-0.1 points

-0.6 to 0.4

2,010NCT01235546

Study of Effectiveness and Safety of Azithromycin-based Extended-spectrum Prophylaxis to Prevent Post Cesarean Infection

Placebo and Standard of Care vs Azithromycin and Standard of Care: Maternal Postpartum Readmission or Unscheduled Visit123 of 992

83 of 1,018

4.2 points

1.6 to 6.9

2,010NCT01235546

Study of Effectiveness and Safety of Azithromycin-based Extended-spectrum Prophylaxis to Prevent Post Cesarean Infection

Placebo With Standard Prophylaxis vs Azithromycin (Zithromax) With Standard Prophylaxis: Maternal Fever81 of 992

51 of 1,018

3.2 points

1.0 to 5.4

2,010NCT01235546

Study of Effectiveness and Safety of Azithromycin-based Extended-spectrum Prophylaxis to Prevent Post Cesarean Infection

Placebo and Standard of Care vs Azithromycin and Standard of Care: Neonatal Intensive Care Unit (NICU) Admission169 of 992

171 of 1,018

0.2 points

-3.0 to 3.5

2,010NCT01235546

Study of Effectiveness and Safety of Azithromycin-based Extended-spectrum Prophylaxis to Prevent Post Cesarean Infection

Placebo and Standard of Care vs Azithromycin and Standard of Care: serious adverse events29 of 992

15 of 1,018

1.4 points

0.2 to 2.8

2,010NCT01235546

Study of Effectiveness and Safety of Azithromycin-based Extended-spectrum Prophylaxis to Prevent Post Cesarean Infection

Provision of Multiple Self-tests vs Referral Vouchers for VCT: deaths from any cause1 of 1,019

1 of 991

-0.0 points

-0.5 to 0.5

2,010NCT03135067

Secondary Distribution of HIV Self-tests: an Innovative Strategy for Promoting Partner Testing and Reducing HIV Risk

Absorb BVS vs XIENCE: deaths from any cause85 of 1,322

44 of 686

0.0 points

-2.4 to 2.2

2,008NCT01751906

ABSORB III Randomized Controlled Trial (RCT)

Absorb BVS vs XIENCE: serious adverse events801 of 1,322

398 of 686

2.6 points

-1.9 to 7.1

2,008NCT01751906

ABSORB III Randomized Controlled Trial (RCT)

Information vs Usual Care: Do-Not-Resuscitate136 of 1,011

144 of 997

-1.0 points

-4.0 to 2.0

2,008NCT04852055

Effect of an Advance Care Planning Intervention

Information vs Usual Care: Do-Not-Hospitalize31 of 1,011

35 of 997

-0.4 points

-2.1 to 1.1

2,008NCT04852055

Effect of an Advance Care Planning Intervention

Neoadjuvant TAS 2 Months Before and During RT vs Radiation Therapy Alone: serious adverse events33 of 1,003

16 of 1,003

1.7 points

0.3 to 3.1

2,006NCT00002597

Radiation Therapy With or Without Antiandrogen Therapy in Treating Patients With Stage I or Stage II Prostate Cancer

ChimeriVax™-JE 4 log10 PFU Vaccine vs Placebo: serious adverse events5 of 1,601

2 of 403

-0.2 points

-1.5 to 0.4

2,004NCT00314132

Safety Study of ChimeriVax™-JE Vaccine to Prevent Japanese Encephalitis.

Guardant Shield Blood Test vs Standard of Care: Assess Colorectal Cancer Screening Completion305 of 1,001

130 of 1,003

17.5 points

14.0 to 21.0

2,004NCT05987709

Study of Colorectal Cancer Screening Options

20mcg Recombinant HEV vs Placebo: deaths from any cause6 of 1,000

1 of 1,000

0.5 points

-0.1 to 1.2

2,000NCT00287469

A Safety and Efficacy Study of the Hepatitis E Vaccine in Nepal.

20mcg Recombinant HEV vs Placebo: serious adverse events143 of 1,000

200 of 1,000

-5.7 points

-9.0 to -2.4

2,000NCT00287469

A Safety and Efficacy Study of the Hepatitis E Vaccine in Nepal.

Screening Group vs No Screening: Number of Participants With an Advance Directive at 12 Months653 of 992

644 of 1,008

1.9 points

-2.2 to 6.1

2,000NCT01699503

Indiana University Dementia Screening Trial

PLWHIV and Mpox Coinfection vs HIV Negative PrEP Users With Mpox Infection: serious adverse events57 of 946

38 of 1,054

2.4 points

0.5 to 4.4

2,000NCT05965427

Morbidity, Mortality And Risk Factors of Mpox in HIV Negative High Risk Sexual Health Clinic Attenders and People Living With HIV

Human Rotavirus (HRV) Group vs HRV Porcine Circovirus (PCV)-Free Group: Number of Participants Reporting Serious Adverse Events (SAEs)251 of 998

262 of 1,002

-1.0 points

-4.8 to 2.8

2,000NCT06025695

Immunogenicity, Reactogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Rotarix Porcine Circovirus (PCV)-Free Liquid Compared to Rotarix Liquid Given in 2-doses in Healthy Chinese Infants Starting at Age 6-16 Weeks

Human Rotavirus (HRV) Group vs HRV Porcine Circovirus (PCV)-Free Group: deaths from any cause1 of 998

0 of 1,002

0.1 points

-0.3 to 0.6

2,000NCT06025695

Immunogenicity, Reactogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Rotarix Porcine Circovirus (PCV)-Free Liquid Compared to Rotarix Liquid Given in 2-doses in Healthy Chinese Infants Starting at Age 6-16 Weeks

Request

GET /api/comparisons/v1

Words from a trial's title, conditions or interventions, its outcome or its groups, or an NCT number.

An outcome counted in participants, the serious adverse events, or the deaths from any cause.

No key needed

Code

Show the call in
curl "https://conductscience.org/api/comparisons/v1?page=174"

Response

The first 2 of this page's 20 results. GET /api/comparisons/v1?page=174

{
  "data": {
    "total": 85013,
    "results": [
      {
        "id": "NCT01235546-8c26fe85",
        "title": "Azithromycin vs Placebo: Participants With Endometritis and/or Wound Infection and/or Other Post-cesarean Infections (Occurring Within 6 Weeks of Delivery)",
        "summary": "62 of 1018 against 119 of 992; risk difference -5.9 points, 95% interval -8.4 to -3.4; NCT01235546, Study of Effectiveness and Safety of Azithromycin-based Extended-spectrum Prophylaxis to Prevent Post Cesarean Infection",
        "record": "/library/comparisons/NCT01235546-8c26fe85",
        "nct_id": "NCT01235546",
        "kind": "outcome",
        "participants": 2010,
        "risk_difference": {
          "value": -0.05905594460992459,
          "lower": -0.08440558029599159,
          "upper": -0.03412829508385831
        },
        "group_1": "62 of 1,018",
        "group_2": "119 of 992",
        "difference": "-5.9 points",
        "interval": "-8.4 to -3.4",
        "trial_title": "Study of Effectiveness and Safety of Azithromycin-based Extended-spectrum Prophylaxis to Prevent Post Cesarean Infection"
      },
      {
        "id": "NCT01235546-8ecfb4a9",
        "title": "Placebo and Standard of Care vs Azithromycin and Standard of Care: Infant Pyloric Stenosis",
        "summary": "1 of 992 against 2 of 1018; risk difference -0.1 points, 95% interval -0.6 to 0.4; NCT01235546, Study of Effectiveness and Safety of Azithromycin-based Extended-spectrum Prophylaxis to Prevent Post Cesarean Infection",
        "record": "/library/comparisons/NCT01235546-8ecfb4a9",
        "nct_id": "NCT01235546",
        "kind": "outcome",
        "participants": 2010,
        "risk_difference": {
          "value": -0.0009565720261106533,
          "lower": -0.006193058943844927,
          "upper": 0.0039355954277207165
        },
        "group_1": "1 of 992",
        "group_2": "2 of 1,018",
        "difference": "-0.1 points",
        "interval": "-0.6 to 0.4",
        "trial_title": "Study of Effectiveness and Safety of Azithromycin-based Extended-spectrum Prophylaxis to Prevent Post Cesarean Infection"
      }
    ],
    "no_events": 33758,
    "columns": [
      {
        "key": "title",
        "label": "Comparison"
      },
      {
        "key": "group_1",
        "label": "With the outcome",
        "under": "group_2"
      },
      {
        "key": "difference",
        "label": "Risk difference, 95% interval",
        "under": "interval"
      },
      {
        "key": "participants",
        "label": "Participants"
      },
      {
        "key": "nct_id",
        "label": "Trial",
        "under": "trial_title"
      }
    ],
    "order": "Most participants first",
    "kinds": {
      "all": 85013,
      "outcome": 33568,
      "serious-adverse-events": 31897,
      "deaths": 19548
    }
  },
  "release": "trial-comparisons-2026-03-23-0.1.0",
  "terms": [
    {
      "source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
      "license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "Freely available. Acknowledgement requested"
    },
    {
      "source": "ClinicalTrials.gov",
      "license": "none stated",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "No license stated"
    }
  ],
  "next": "/api/comparisons/v1?page=175",
  "request_id": "_A4ZhnomfwGdRT_h"
}

Ask about these results. The first 10 go in the prompt.

About this data
Holds
85,013 comparisons
From ClinicalTrials.gov. Counted 10 Nov 2026.
Release
23 Mar 2026
trial-comparisons-2026-03-23-0.1.0
Checked
20 of 20 review comparisons traced to ClinicalTrials.gov, and all 510,078 numbers calculated again apart from the builder agree
Access
Open
No account. 60 calls a minute from one address.

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

Genes

NCBI Gene

One gene with its proteins, patents, drugs, trials, grants and papers.

Trials

ClinicalTrials.gov

Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.

Sequences

Patent publications

Paste a sequence and see the patents that disclose it.

Opens sequences.conductscience.org

For software

Read Trial comparisons from software.

Every answer on this page is also JSON, under /api/comparisons/v1. No key.

GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome

Ask an assistant

  • In FOURIER, how did serious adverse events compare between evolocumab and placebo?
  • Which metformin trials reported deaths, and what was the risk difference?
  • What was the number needed to treat for HELIOS-B's composite outcome?
  • Which placebo-controlled heart failure trials had the most participants?